tweetindex
TH

JAMA Oncology

@JAMAOnc · Chicago, IL · joined 15 Sep 2014

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

50 783Followers
506Following
18 808Posts total
10.4KViews on collected posts

โพสต์ล่าสุด

@JAMAOnc 1% by 2026!. 4 views · 0 likes · 0 reposts · 0 replies Open on X →
@JAMAOnc https://t.co/WyBtYmPu1j
GIF
93 views · 2 likes · 0 reposts · 0 replies Open on X →
Prebiopsy #MRI use before #ProstateCancer biopsy increased in the US from 2017 to 2026, reaching 64.1% of biopsy-naive patients, but uptake remained incomplete. https://t.co/FEoD6qtwCW https://t.co/YvLQteqZrC
2K views · 20 likes · 5 reposts · 4 replies Open on X →
💬Editorial: In HPV 16–positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus pembrolizumab demonstrated activity in immune checkpoint inhibitor–naive disease but not after prior immune checkpoint inhibitor exposure. https://t.co/fwYwO4jAPy https://t.co/tlzO6UlqFe
1.9K views · 5 likes · 4 reposts · 0 replies Open on X →
Meta-analysis: Among #HeadAndNeckCancer patients with PD-L1 CPS <1, #ImmuneCheckpointInhibitors were linked to poorer survival outcomes, including significantly reduced overall survival in recurrent/metastatic disease. https://t.co/6XQjl1DujV https://t.co/0FLl1PIve7
2.9K views · 22 likes · 7 reposts · 0 replies Open on X →
In #HPV16-positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus #Pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. https://t.co/MmBkFHDrK4 https://t.co/KNID0Co
1.8K views · 15 likes · 2 reposts · 1 replies Open on X →
In persistent, recurrent, or metastatic #CervicalCancer, first-line #Pembrolizumab plus chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years, with no new safety signals observed. https://t.co/kHFZZRmovN 1.9K views · 7 likes · 3 reposts · 2 replies Open on X →

เทียบกับบัญชีขนาดเดียวกัน

7 โพสต์จาก 90 วันที่ผ่านมา เทียบกับช่วง 10K–100K ผู้ติดตาม การเข้าถึงปกติสำหรับขนาดนี้ แต่การตอบสนองอ่อนกว่าส่วนใหญ่.

ยอดดูมัธยฐาน1 854บัญชีนี้953ค่ามัธยฐานของ 10K–100K
การเข้าถึง, %3.65%บัญชีนี้3.62%ค่ามัธยฐานของ 10K–100K
การมีส่วนร่วม, %1.01%บัญชีนี้1.51%ค่ามัธยฐานของ 10K–100K
ตัวชี้วัดบัญชีนี้ค่ามัธยฐานของ 10K–100Kอัตราส่วน
ยอดดูมัธยฐานต่อโพสต์1 8549531.95×
การเข้าถึง (ยอดดู ÷ ผู้ติดตาม)3.65%3.62%1.01×
อัตราการมีส่วนร่วม1.01%1.51%0.67×

บัญชีอื่นในช่วงนี้ →   เปรียบเทียบกับบัญชีอื่น →   ค่าอ้างอิงเหล่านี้คำนวณอย่างไร →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1.9K10 Sep
1.8K17 Sep
2.9K
1.9K18 Sep
2K
93
419 Sep

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.64%10 Sep
1.01%17 Sep
1.01%
0.49%18 Sep
1.48%
2.15%
0.00%19 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.51%.

What the audience does

Likes62.8%71 in total
Reposts18.6%21 in total
Replies6.2%7 in total
Bookmarks12.4%14 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

บัญชีที่คล้ายกัน